GURU.Markets stock price, segment price, and overall market index valuation
The company's share price GSK plc
GSK (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer division, focused on innovative drugs and vaccines. Its share price now depends on R&D success, particularly in infectious diseases and immunology.
Share prices of companies in the market segment - Pharma holding
GSK is a British pharmaceutical giant with key segments in vaccines, HIV treatment, and respiratory disease treatment. We classify it as part of the Pharma Holdings sector, and the chart below shows the overall dynamics of the entire industry of large drugmakers.
Broad Market Index - GURU.Markets
GSK (GlaxoSmithKline) is a British pharmaceutical giant with strong positions in vaccines and drugs for infectious and respiratory diseases. Its scale makes it an important component of the GURU.Markets index. The chart below represents the entire market. Find out how GSK shares compare to the broader market.
Change in the price of a company, segment, and market as a whole per day
GSK - Daily change in the company's share price GSK plc
For GSK, the British pharmaceutical giant, daily price changes reflect its sensitivity to the success of new drugs and vaccines. The graph of these fluctuations is unspectacular, but it is an important component of the formulas on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma holding
GSK plc is a major British pharmaceutical company. This chart shows the average daily volatility of the entire industry. Comparing this to GSK's performance, which focuses on vaccines and infectious disease treatments, helps assess its stability compared to its oncology-focused competitors.
Daily change in the price of a broad market stock, index - GURU.Markets
GSK (GlaxoSmithKline) is a British pharmaceutical giant. The pharmaceutical sector can be defensive, but breakthroughs and setbacks in drug development create their own volatility. The chart below shows overall market dynamics, allowing you to assess how GSK fits into the global landscape.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization GSK plc
GSK, the British pharmaceutical giant, has shifted its focus to vaccines and innovative drugs over the past year after spinning off its consumer division. The stock price performance shown in the chart reflects the market's assessment of this new, more focused strategy.
Annual dynamics of market capitalization of the market segment - Pharma holding
Following the spinoff of its consumer business, GSK plc has focused on developing innovative drugs and vaccines. Its future now depends entirely on the success of R&D and the commercialization of new products, particularly in respiratory diseases. The chart will reveal whether investors believe in this new, more focused strategy.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
GSK plc (GlaxoSmithKline) is a major British pharmaceutical company that has focused on vaccines and specialty drugs after spinning off its consumer business. Its performance depends on the success of its R&D, particularly in respiratory diseases and HIV. A comparison with the market will reveal how investors view its new, more focused strategy.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization GSK plc
For pharmaceutical giant GSK, the chart reflects the life cycle of its key products. Monthly price fluctuations are driven by news about clinical trials of new drugs, patent expirations on old ones, and strategic decisions regarding the sale of consumer brands.
Monthly dynamics of market capitalization of the market segment - Pharma holding
This chart shows the dynamics of the entire pharmaceutical sector. For GSK, one of the global giants, it serves as a backdrop. It illustrates how the company, with its focus on vaccines and innovative drugs, is transforming its portfolio against the backdrop of overall industry trends.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
GSK is a British pharmaceutical giant that, after splitting its businesses, focused on innovative drugs and vaccines. Like other large pharmaceutical companies, it has defensive qualities. The chart below shows general market fluctuations, which suggest that GSK's performance is more dependent on success in new drug development than on the economy.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization GSK plc
GSK plc (formerly GlaxoSmithKline), the British pharmaceutical giant, has focused on vaccines and innovative medicines since spinning off its consumer business. Its weekly stock price is now more dependent on news of sales of the Shingrix shingles vaccine and progress in developing new drugs.
Weekly dynamics of market capitalization of the market segment - Pharma holding
GSK, after its split and focus on innovative drugs and vaccines, is striving to outperform the big pharma sector. Investors are comparing its performance with its competitors to assess the effectiveness of its new strategy. The chart shows whether the company is succeeding in breaking out of the general trend through R&D breakthroughs.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
GSK (GlaxoSmithKline) is a British pharmaceutical giant. Big pharma stocks are often considered "defensive" due to the stability of demand for their medications. The chart will show whether GSK's weekly fluctuations actually smooth out overall market volatility, especially during downturns.
Market capitalization of the company, segment and market as a whole
GSK - Market capitalization of the company GSK plc
The market capitalization of GSK plc, the British pharmaceutical giant, shows how the market values it following the spinoff of its consumer business (Haleon). The chart reflects the company's focus on innovative drugs and vaccines, particularly in respiratory diseases and HIV. Investors are watching to see whether the rejuvenated GSK can accelerate its growth.
GSK - Share of the company's market capitalization GSK plc within the market segment - Pharma holding
GSK plc (GlaxoSmithKline) is a British pharmaceutical giant with a strong market share in vaccines and specialty drugs, particularly in HIV and respiratory diseases. Its market capitalization reflects successful restructuring and a focus on innovative drugs.
Market capitalization of the market segment - Pharma holding
The chart below shows the trillion-dollar value of the global pharmaceutical industry. GSK is a British giant that, after spinning off its consumer business, focused on innovative drugs and vaccines. The dynamics of this market reflect the constant pursuit of scientific breakthroughs, and GSK is banking on its expertise in immunology and genetics.
Market capitalization of all companies included in a broad market index - GURU.Markets
GSK plc is a British pharmaceutical giant with strong positions in vaccines and respiratory treatments. Its market capitalization reflects the value of its scientific heritage and product portfolio. The chart below shows the relative importance of major European healthcare players.
Book value capitalization of the company, segment and market as a whole
GSK - Book value capitalization of the company GSK plc
GSK (GlaxoSmithKline) is built on its powerful R&D centers, particularly strong in vaccines and infectious disease treatments, as well as its global manufacturing network. This chart tells the story of a pharmaceutical company that, after spinning off its consumer business, focused on innovative medicines and strengthening its scientific and manufacturing foundations.
GSK - Share of the company's book capitalization GSK plc within the market segment - Pharma holding
Mondelez International, owner of brands such as Oreo and Cadbury, has a global production network. The chart shows the company's share of physical assets in the food industry. These include dozens of confectionery factories and bakeries around the world that produce beloved sweets.
Market segment balance sheet capitalization - Pharma holding
GSK is a global pharmaceutical giant. Its asset chart demonstrates its capital intensity. GSK is particularly focused on research-intensive capital in the vaccine field, which requires not only advanced R&D centers but also massive and sophisticated manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
GSK plc, formerly GlaxoSmithKline, is a British pharmaceutical giant with a strong focus on vaccines and treatments for respiratory and infectious diseases. Its net worth is its global network of R&D and manufacturing centers, which create the foundation for public health.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - GSK plc
GSK plc is a British pharmaceutical giant. The modest premium to its stock reflects the strength of its vaccine business and several new drugs, but also investor concerns about its ability to compete with faster-growing pharmaceutical companies.
Market to book capitalization ratio in a market segment - Pharma holding
GSK plc is a British pharmaceutical company with strong positions in vaccines and HIV treatments that has spun off its consumer business. This chart shows how the market views its focused strategy on innovative drugs and the potential of its R&D pipeline to create future hits.
Market to book capitalization ratio for the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that has focused on innovative medicines and vaccines since spinning off its consumer division. This chart shows the average market valuation of the business. Against this backdrop, its valuation reflects the potential of its research and development in infectious diseases and immunology.
Debts of the company, segment and market as a whole
GSK - Company debts GSK plc
For GSK, the British pharmaceutical giant, its debt policy reflects its strategy to focus on innovative drugs and vaccines after spinning off its consumer business. The company uses debt to fund R&D and for acquisitions aimed at strengthening its core pharmaceutical portfolio.
Market segment debts - Pharma holding
GSK plc (GlaxoSmithKline), following the spinoff of its consumer business (Haleon), has focused on innovative medicines and vaccines. This requires significant investment in R&D. The company's debt policy is aimed at maintaining financial flexibility for investment in development and potential acquisitions. This chart shows the financial profile of the new GSK.
Market debt in general
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on innovative medicines and vaccines. This move was aimed at accelerating growth. This total debt chart helps understand the financial environment in which GSK is implementing its new strategy, which requires significant investment in R&D.
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on innovative medicines and vaccines. This chart shows its financial structure after the reorganization. Debt is used to fund R&D and transactions aimed at strengthening its development pipeline.
Market segment debt to market segment book capitalization - Pharma holding
GSK plc (GlaxoSmithKline) is a British pharmaceutical company that focused on vaccines and specialty medicines after spinning off its consumer business. This chart shows how the company's debt policy supports its strategy. It compares its debt to the market capitalization of the pharmaceutical industry as a whole, reflecting its financial health.
Debt to book value of all companies in the market
GSK, the British pharmaceutical giant, has a mature and diversified business. This chart compares its financial policy with the overall market. It shows that the company's debt burden is moderate compared to the average debt level across the economy, reflecting its balanced approach.
P/E of the company, segment and market as a whole
P/E - GSK plc
This chart for GSK, a British pharmaceutical company, shows its valuation after focusing on innovative drugs and vaccines. The P/E reflects investors' confidence in the success of this new focus, particularly its strong positions in respiratory diseases and HIV, which should drive future growth.
P/E of the market segment - Pharma holding
GSK plc (GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines, HIV treatments, and respiratory diseases. The company underwent a restructuring, spinning off its consumer business. This chart shows the average valuation for the pharmaceutical industry, helping investors understand how the market views GSK's updated strategy.
P/E of the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines and treatments for respiratory and HIV infections. Following the spinoff of its consumer business (Haleon), the company focused on innovative medicines. Its valuation now depends more on the success of its R&D pipeline than on the overall economic trends shown here.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business, focused on innovative medicines and vaccines. This chart reflects expectations for its R&D pipeline. The valuation hinges on the success of new products, particularly in respiratory diseases and HIV, which are expected to drive growth.
%20P%2FE%20GSK%20plc&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-GSK-plc&v=1772513553389 "Chart of the company's future (projected) P/E GSK plc")
Future (projected) P/E of the market segment - Pharma holding
GSK plc (GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines, respiratory disease treatments, and HIV. This chart reflects the market's assessment of its scientific potential. Comparing its profit forecasts with the sector reveals how confident investors are in its ability to bring new, successful products to market.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-holding&v=1772513553404 "Future (projected) P/E graph of the market segment - Pharma holding")
Future (projected) P/E of the market as a whole
GSK plc (GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business, focused on innovative drugs and vaccines. Its success depends on R&D. Against the backdrop of overall market trends, as illustrated by this chart, investors are assessing GSK's ability to expand its portfolio with new, successful drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513553486 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines, HIV treatments, and respiratory diseases. Its profits depend on the success of its core products and its ability to bring new drugs to market. This chart shows financial results after the spinoff of its consumer products business (Haleon).
Profit of companies in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company focused on innovative medicines and vaccines. After spinning off its consumer business, the company focused on science, particularly in infectious diseases and immunology. Its success in developing new drugs is a key driver of the pharmaceutical industry's growth.
Overall market profit
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company specializing in the development and production of medicines and vaccines. The company has strong positions in respiratory disease treatment, HIV treatment, and vaccine production. Its contribution to global healthcare and financial performance reflect both current medical needs and advances in scientific innovation.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company GSK plc
GSK plc (GlaxoSmithKline) has focused on vaccines and specialty medicines since the spinoff of its consumer business. This chart reflects expectations for sales of its key product, the shingles vaccine Shingrix, as well as progress in developing new drugs.
%20profit%20of%20the%20company%20GSK%20plc&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-GSK-plc&v=1772513553737 "Graph of future (projected) profit of the company GSK plc")
Future (predicted) profit of companies in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company focused on vaccines and specialty medicines following the spinoff of its consumer business. The forecast chart reflects profit expectations for the entire pharmaceutical industry. It allows one to assess the success of GSK's strategy to renew its R&D portfolio.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-holding&v=1772513553796 "Graph of future (predicted) profits of companies in a market segment - Pharma holding")
Future (predicted) profit of the market as a whole
British pharmaceutical giant GSK's profit forecast hinges on the success of its key vaccine and specialty drug products. This chart reflects expectations for growth in sales of the Shingrix shingles vaccine and HIV treatments, as well as development progress across its product portfolio.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513553836 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - GSK plc
GSK plc (GlaxoSmithKline) is a British pharmaceutical company that focused on vaccines and specialty medicines after spinning off its consumer business. This chart shows how investors estimate the new company's revenue. The multiple reflects expectations for its vaccine portfolio and new developments.
P/S market segment - Pharma holding
GSK plc (GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines, HIV treatments, and respiratory diseases. This metric reflects the average revenue estimate in the pharmaceutical industry and helps assess how investors perceive GSK's product portfolio and research potential following the spinoff of its consumer business.
P/S of the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business, focused on innovative medicines and vaccines. This chart, which displays GSK's average revenue estimates, helps understand how the market views its updated strategy and the potential of its scientific portfolio.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer division, has focused on innovative medicines and vaccines. Particular attention is paid to the respiratory syncytial virus (RSV) vaccine. This chart shows how investors estimate its future revenue from its new, more focused product portfolio.
%20P%2FS%20GSK%20plc&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-GSK-plc&v=1772513553961 "The graph of the company's future (projected) P/S GSK plc")
Future (projected) P/S of the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline), after spinning off its consumer division, has focused on innovative drugs and vaccines. This chart shows how the market is viewing this new, more focused strategy. Do investors believe in the potential of its R&D, particularly in infectious diseases and immunology?
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20holding&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-holding&v=1772513554049 "Future (projected) P/S market segment graph - Pharma holding")
Future (projected) P/S of the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company focused on vaccines and specialty medicines following the spinoff of its consumer business. Its growth depends on the success of new products, particularly in respiratory diseases and HIV. GSK's progress is important for the entire sector and influences overall sentiment, as reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513554067 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales GSK plc
GSK plc (GlaxoSmithKline) is a British pharmaceutical company focused on developing innovative medicines and vaccines. Its revenue depends on the success of key products in areas such as respiratory diseases, HIV, and oncology. This chart shows the commercial performance of its product portfolio.
Sales of companies in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines, HIV treatments, and respiratory diseases. After spinning off its consumer division, the company focused on innovative biopharma. This chart shows overall pharmaceutical sales, demonstrating the competitive landscape in which GSK is focusing on science.
Overall market sales
GSK plc (GlaxoSmithKline) is a British pharmaceutical company, a global leader in vaccines and specialized medicines, such as those for HIV and respiratory diseases. This overall economic activity chart is indirectly important for GSK, as it determines the solvency of global healthcare systems, which are the primary buyers of its products.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company GSK plc
GSK plc (GlaxoSmithKline) is a British pharmaceutical company focused on vaccines and specialty therapies, particularly in HIV and respiratory diseases. Future revenue depends on the success of its key products, such as the shingles vaccine. This chart reflects analyst sales forecasts for the company's drug and vaccine portfolio.
%20sales%20of%20the%20company%20GSK%20plc&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-GSK-plc&v=1772513554259 "Schedule of future (projected) sales of the company GSK plc")
Future (projected) sales of companies in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company specializing in vaccines, HIV treatments, and respiratory treatments. This chart shows projected revenues for the entire pharmaceutical sector. It provides insight into overall healthcare spending trends, which is important context for evaluating GSK's portfolio.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-holding&v=1772513554430 "Schedule of future (projected) sales of companies in the market segment - Pharma holding")
Future (projected) sales of the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company with strong positions in vaccines and infectious disease treatments. Demand for its products, particularly vaccines, is often driven by government healthcare programs. This dynamic, reflecting the overall state of the economy, influences the budgetary capacity of governments around the world to fund mass vaccinations and drug procurement.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513554468 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that focused on vaccines and specialty medicines after spinning off its consumer business. This chart shows the results of this transformation. The company's success now depends on its innovations in respiratory diseases, HIV, and oncology.
Market segment marginality - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a global pharmaceutical company with strong positions in vaccines, HIV, and respiratory diseases. The company focuses on innovation and science to expand its portfolio with new drugs. This metric demonstrates how successful products and research efficiency impact profitability compared to pharmaceutical industry competitors.
Market marginality as a whole
GSK plc (GlaxoSmithKline) is a British pharmaceutical company that has focused on innovative medicines and vaccines since spinning off its consumer business. This chart shows average profitability. It demonstrates GSK's strategy of increasing profitability by focusing on high-margin products that require strong R&D.
Employees in the company, segment and market as a whole
Number of employees in the company GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on innovative medicines and vaccines. This chart shows the team working at the restructured company. The staffing dynamics reflect this new strategy and focus on R&D in areas such as infectious diseases and immunology.
Share of the company's employees GSK plc within the market segment - Pharma holding
This chart illustrates the scale of GSK plc (formerly GlaxoSmithKline) as one of the world's leading manufacturers of medicines and vaccines. Following the spinoff of its consumer division, its share of pharmaceutical employees has become more focused on innovative drugs and vaccines, particularly in infectious diseases and immunology.
Number of employees in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company, a global leader in vaccines and treatments for respiratory and infectious diseases. Scientific research is at the core of its business. This chart illustrates the importance of R&D in the pharmaceutical industry, where GSK is one of the largest and oldest research centers.
Number of employees in the market as a whole
GSK plc is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on vaccines (especially Shingrix for shingles) and specialty drugs (HIV, oncology). This chart reflects the economic base that funds healthcare. Stable employment allows healthcare systems to pay for their innovative vaccines and drugs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company GSK plc (GSK)
GSK (GlaxoSmithKline) is a British pharmaceutical giant focused on vaccines and specialty drugs. Its high employee ratio reflects the value of its research and development (R&D) and proprietary product portfolio.
%20of%20the%20company%20GSK%20plc%20(GSK)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-GSK-plc-GSK&v=1772513554979 "Chart of market capitalization per employee (in thousands of dollars) of the company GSK plc (GSK)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma holding
Following the spinoff of its consumer business (Haleon), GSK plc (GSK) became a pure-play biopharmaceutical company focused on vaccines and R&D. This chart shows market capitalization per employee, reflecting the market's confidence in its updated, science-focused strategy.
%20by%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-holding&v=1772513555025 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma holding")
Market capitalization per employee (in thousands of dollars) for the overall market
GSK plc (GlaxoSmithKline) is a British pharmaceutical company focused on vaccines and specialty medicines following the spinoff of its consumer business. This chart shows how the market views its updated strategy. A high valuation per employee will depend on the success of its R&D pipeline in promising medical areas.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513555055 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company GSK plc (GSK)
GSK plc is a British pharmaceutical giant that, after spinning off its consumer business (Haleon), focused on innovative medicines and, crucially, vaccines (Shingrix). This chart demonstrates the effectiveness of this new, more focused R&D. Success in creating blockbuster vaccines is key to increasing profitability per scientist.
%20Chart%20GSK%20plc%20(GSK)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-GSK-plc-GSK&v=1772513555072 "Company Profit Per Employee (in thousands of dollars) Chart GSK plc (GSK)")
Profit per employee (in thousands of dollars) in the market segment - Pharma holding
GSK plc is a British pharmaceutical giant (vaccines, R&D). This chart shows the average for the entire pharmaceutical industry. This sector is a "blockbuster business." Average employee profitability is high because R&D (creating patents, especially for vaccines) generates high profits, covering the costs of thousands of scientists.
%20in%20the%20market%20segment%20-%20Pharma%20holding&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-holding&v=1772513555084 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma holding")
Profit per employee (in thousands of dollars) for the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company focused on developing vaccines and specialty medicines. The company recently spun off its consumer healthcare business. This chart shows how focusing on innovative biopharma impacts employee financial performance.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513555186 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee GSK plc (GSK)
GSK plc is a British pharmaceutical company focused on developing innovative medicines and vaccines. This chart illustrates a typical pharmaceutical industry model: high revenue per employee is achieved through the successful commercialization of patented products, the result of years of scientific research.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-GSK-plc-GSK&v=1772513555217 "Sales chart per company employee GSK plc (GSK)")
Sales per employee in the market segment - Pharma holding
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company focused on vaccines and specialty medicines following the spinoff of its consumer business (Haleon). This chart shows the average revenue per employee in this segment, demonstrating the effectiveness of their updated R&D strategy compared to other pharma giants.
Sales per employee for the market as a whole
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical company. After spinning off its consumer business (Haleon), they focused on innovative medicines and vaccines (they are particularly known for their vaccines). This chart shows how their R&D in vaccines and specialty medicines generates revenue.
Short shares by company, segment and market as a whole
Shares shorted by company GSK plc (GSK)
GSK plc (GlaxoSmithKline) is a British pharmaceutical company that has focused on vaccines and therapeutics since spinning off its consumer business (Haleon). The bearish sentiment seen in this chart may be related to concerns about lawsuits (related to Zantac) or the lack of clear blockbusters in the pipeline.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-GSK-plc-GSK&v=1772513555341 "Short Shares Chart for the Company GSK plc (GSK)")
Shares shorted by market segment - Pharma holding
GSK plc is a British pharmaceutical giant that, after spinning off its consumer business (Haleon), focused on innovative drugs and vaccines (especially for shingles). This chart shows the overall sentiment towards the sector. It reflects investor concerns about the R&D productivity of "big pharma" and pressure on drug prices.
Shares shorted by the overall market
GSK is a British pharmaceutical giant focused on vaccines and treatments for respiratory and infectious diseases. It's a classic "defensive" sector. This chart reflects the overall level of fear in the market. When pessimism increases (the chart rises), investors seek stability in companies whose demand (for drugs and vaccines) is unaffected by crises.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator GSK plc (GSK)
GSK is a global pharmaceutical giant that, after spinning off its consumer business (Haleon), focused on vaccines (Shingrix) and R&D. This chart measures momentum. "Oversold" (below 30) often reflects panic due to legal risks (the Zantac lawsuit) or R&D failures. "Overbought" (above 70) signals optimism about new vaccines or advances in oncology.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-GSK-plc-GSK&v=1772513555392 "RSI 14 indicator chart for the company's stock GSK plc (GSK)")
RSI 14 Market Segment - Pharma holding
GSK (GSK) is a British pharmaceutical giant focused on vaccines (especially Shingrix) and innovative drugs, particularly for HIV. This metric measures the overall momentum of the Big Pharma sector. It helps understand whether GSK is oversold due to litigation risks (Zantac) or the entire industry is being chilled by regulatory pressure.
RSI 14 for the overall market
GSK plc is a British pharmaceutical giant focused on innovation in vaccines and specialized drugs (HIV, oncology). Their business is driven by science, not market cycles. This chart, showing investor euphoria or panic, has little impact on demand for their life-saving drugs, making GSK shares attractive during times of market "panic."
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast GSK (GSK plc)
The average price target on this chart is an estimate of how GSK will cope with the patent cliff and lawsuits (Zantac). When making forecasts, analysts weigh the fading of old patents against the potential for new R&D (vaccines, oncology). Consensus is the belief (or doubt) that the company's R&D pipeline will be able to offset the risks.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-GSK-GSK-plc&v=1772513555511 "A chart showing analyst consensus forecasts for the expected stock price. GSK (GSK plc)")
The difference between the consensus estimate and the actual stock price GSK (GSK plc)
GSK, the British pharmaceutical giant, has focused on innovative drugs and vaccines (especially for respiratory diseases) since spinning off its consumer business (Haleon). This chart shows analysts' confidence in their R&D pipeline and the success of new vaccine launches. It reflects the gap between the consensus estimate and the current share price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-GSK-GSK-plc&v=1772513555589 "A chart showing the difference between the consensus forecast and the actual stock price. GSK (GSK plc)")
Analyst consensus forecast for stock prices by market segment - Pharma holding
GSK plc is a British pharmaceutical giant that, after spinning off its consumer business (Haleon), focused on innovative vaccines (Shingrix) and drugs (HIV). This chart shows analysts' overall expectations for "big pharma." It reflects whether experts believe the industry's R&D pipelines will be successful.
Analysts' consensus forecast for the overall market share price
GSK plc is a British pharmaceutical giant focused on vaccines and innovative drugs. The healthcare sector is considered defensive. However, this overall market sentiment chart influences GSK. During periods of market optimism, investors may prefer riskier biotechs. In times of crisis, they value GSK's stable cash flow and dividends.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index GSK plc
GSK plc (formerly GlaxoSmithKline) is a British pharmaceutical giant. Following the recent spinoff of its consumer business (Haleon), the company has shifted its focus entirely to innovative medicines, particularly vaccines. This chart reflects their new strategy. A key driver is their blockbuster shingles vaccine, Shingrix.
AKIMA Market Segment Index - Pharma holding
GSK (formerly GlaxoSmithKline) is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on innovative vaccines and specialty medicines. This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this new, focused strategy differentiate GSK from the average pharmaceutical company?
The AKIM Index for the overall market
GSK plc is a British pharmaceutical company that, after spinning off its consumer business (Haleon), focused on innovative drugs and vaccines (particularly in respiratory diseases and HIV). This chart, which reflects the market average, provides a macro backdrop. It helps assess how GSK, focused on its R&D portfolio, compares to the broader economic trends that influence investor sentiment in the healthcare sector.
